• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 20th March 2018

Minimal Access Surgery – Why Don’t We Do More?

OHE Consulting publishes a report on the barriers to the uptake of minimal access surgery in the NHS and private sector. Surgical practice has come a long way, barely recognisable from the risky “art” form it once was. With the…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

OHE Consulting publishes a report on the barriers to the uptake of minimal access surgery in the NHS and private sector.

Surgical practice has come a long way, barely recognisable from the risky “art” form it once was. With the scientific advancement of anaesthesia, infection control, surgical equipment and surgeon skill, surgery is now an integral part of health care and treatment provision. The focus now is on improving surgical precision and minimising the adverse impact of surgery on patients.
 
Minimal access surgery (MAS – also known as minimally invasive, laparoscopic or keyhole surgery) has been around for thirty years or more. When used appropriately, it can dramatically improve patient recovery, whilst achieving the same surgical outcomes as open surgery. This results in an improved patient experience and quality of life, and shorter inpatient stays: good news for patients and for our financially and physically constrained NHS. 
 
Despite this, there is variable adoption of MAS across NHS Trusts, and the utilisation of minimal access techniques is low for many procedures. Given the continuing evolution of surgical techniques, including the forthcoming robotic era, it is important to understand how surgical technologies are adopted in the health care system in the UK and what challenges are faced when making implementation decisions.
 
In an OHE Consulting Report funded by CMR Surgical, we investigate the barriers to uptake of MAS in the UK. 
 
A review of the literature demonstrates the growing evidence base supporting the clinical and cost-effectiveness of MAS for three specific procedures: hysterectomy, ventral/incisional hernia repair, and lower anterior resection. However, despite the benefits, uptake of MAS is highly variable.
 
To better understand why, we interviewed 12 key stakeholders and decision-makers – surgeons working in the NHS and private sector, clinical directors, and finance directors – to identify the potential barriers affecting the uptake of MAS and offer solutions.
 
Surgeon preferences play a key role in choice of surgical routine, and are a product of experience, interpretation of the evidence-base, and core medical training – with those professionals more recently trained being more familiar with and open to MAS. The importance of a “clinical champion” is apparent, and in settings where such an individual is lacking, the necessary enthusiasm to drive change and secure investment in innovation may pose a barrier to MAS. In some settings a cultural change is required; better equipping patients with information could provide a catalyst to increase the uptake of MAS.
 
A lack of suitably trained clinical staff was identified as a key barrier. Whilst there are plenty of training opportunities for surgeons in the UK, a lack of funding and time to access them appear to be the main issue. Investment in training and incentives to take-up the opportunities should be encouraged, and the importance of ‘on-the-job’ training should be recognised.
 
Constrained NHS capacity should be seen as a motivator for MAS; the slightly longer operating time (a matter of minutes or hours) is more than offset by a shorter in-patient hospital stay (a matter of days). Whilst the trade-off is generally well understood, improved financial and systems oversight is required, and a reduction in “silo-thinking” which prevails where short-term budgetary constraints are allowed to drive decision-making. 
 
Technological innovation can support an expansion of the application of MAS, either to new procedures or by making MAS amenable to more surgeons. Robotic-assisted MAS represents the biggest technological innovation of today, but the high costs associated with its delivery are currently prohibitive in most settings.
 
There is a growing awareness of the need to promote innovation which can realise improvements in patient care and outcomes, and help to build a sustainable health system for the future. MAS is one such innovation, but there is a need to address a number of these barriers to harness the benefits of MAS.
 
Click here to download the full report.
 
  • Health Care Systems
  • Economics of Innovation
  • Consulting Reports

Related News

NGS report_AdobeStock_406823942_landscape
  • News
  • July 2023

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
  • News
  • October 2020

Opportunities to Increase Efficiency in Healthcare

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!